A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

Inclusion Criteria

• •\<Ia part\>
• •Patients with differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) after total thyroidectomy.
• •Patients with radically unresectable, recurrent, metastatic disease who are judged by the principal investigator or sub-investigator (hereinafter, "principal/sub-investigators") to be refractory to or intolerant of standard-of-care therapy.
• •\<Ib part\>
• •Patients with radically unresectable, recurrent, metastatic disease who are RAI naive
• •Patients with measurable lesions. \<Ia/Ib part\>
• •Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 and stable general condition.
• •Patients expected to survive for at least 6 additional months based on clinical symptoms and physical examination findings.